铜绿假单胞注射液联合PC方案治疗晚期肺腺癌的疗效评价
Effectiveness of Paclitaxel-carboplatin Regimen Combined with Pseudomonas aeruginosa Mannose-sensitive Hemagglutinin Injection for Lung Adenocarcinoma
-
摘要:目的 评价铜绿假单胞菌注射液(PA-MSHA)联合PC方案一线治疗晚期肺腺癌的疗效。方法 收集60例肺腺癌初治患者应用PC方案化疗, 分为两组: 实验组30例, 对照组30例, 实验组同时加用铜绿假单胞菌注射液。治疗结束后进行疗效评价, 并在治疗前后分别检测患者的免疫功能指标(CD3+, CD4+, CD8+, NK)的变化情况。结果 实验组的疾病控制率66.7%(DCR)高于对照组46.7%, 差异有统计学意义(P < 0.05);实验组治疗后较对照组体能状况明显改善; 对照组化疗后免疫功能指标(CD3+, CD4+, CD8+, NK)较化疗前降低.差异有统计学意义(P < 0.05), 而实验组较化疗前升高(P < 0.05), 差异有统计学意义。结论 铜绿假单胞菌注射液与PC方案联合治疗晚期肺腺癌可显著提高疾病控制率, 改善患者化疗后体力状况, 明显提高晚期肺腺癌患者的细胞免疫功能, 对化疗导致的免疫功能损害具有改善作用。Abstract:Objectives To evaluate the effectiveness of chemotherapeutic paclitaxel carboplatin (PC) regimen combined with Pseudomonas aeruginosa mannose-sensitive hemagglutinin (PA MSHA) injection for treating lung adenocarcinoma.Methods A total of 60 patients with lung adenocarcinoma were randomly assigned to receive either chemotherapy alone (control group or G1, n = 30) or combined with PA-MSHA injection (experimental group or G2, n = 30). The therapeutic effect was evaluated after completion of the treatment. The immune function of the patients and other indicators were also detected before and after therapy.Results The disease control rate was significantly higher in G2 (66.7 %) than in G1 (46.7 %; P < 0.05). Compared with the results before chemotherapy, the immune function of the patients in G1 was decreased whereas those in G2 increased. After chemotherapy, the immune function of the patients in G2 was better than those in G1 (P < 0.05).Conclusion The PC regimen combined with PA-MSHA injection significantly improves the response rate of patients with lung adenocarcinoma and enhances their immune function. PA-MSHA has been proven as an ideal supplementary therapy for lung adenocarcinoma.
下载: